Abstract
Elevated levels of exhaled nitric oxide at a flow of 50 mL·s−1 (FENO50) are an important indicator of Th2 airway inflammation and may aid clinicians in the diagnosis and monitoring of asthma. This study aimed to derive Global Lung Function Initiative reference equations and the upper limit of normal for FENO50.
Available individual FENO50 data were collated and harmonised using consensus-derived variables and definitions. Data collected from individuals who met the harmonised definition of “healthy” were analysed using generalised additive models of location shape and scale (GAMLSS) technique.
Data were retrospectively collated from 34 782 individuals from 34 sites in 15 countries, of whom 8022 met the definition of healthy (19 sites, 11 countries). Overall, height, age and sex only explained 12% of the between-subject variability of FENO50 (R2=0.12). The addition of NO device was a predictor of FENO50 and between-subject variability, such that the healthy range of values and the upper limit of normal varied depending on which device was used. The range of FENO50 values observed in healthy individuals was also very wide, and the heterogeneity was partially explained by the device used. The heterogeneity between sites remained within a sub-set of data where FENO50 was measured using the same device and a stricter definition of health (n=1027).
Available FENO50 data collected from different sites using different protocols and devices was too variable to develop a single all-age reference equation. Further standardisation of NO devices and measurement is required before population reference values might be derived.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Cole Bowerman reports personal payments for work on this manuscript through the GLI CRC subsidized by the ERS, and a leadership role as Junior Executive for Global Lung Function Initiative.
Conflict of interest: Sanja Stanojevic reports consulting fees from Chiesi Pharmaceuticals; lecture honoraria from Vyaire Medical; advisory board participation with Ndd technologies; outside the submitted work.
Conflict of interest: Anh Tuan Dinh-Xuan reports lecture honoraria from Circassia, outside the submitted work.
Conflict of interest: All other authors have nothing to disclose.
- Received March 6, 2023.
- Accepted September 22, 2023.
- Copyright ©The authors 2023. For reproduction rights and permissions contact permissions{at}ersnet.org